

## West Region Hospital Antibigrams – 2024

Note: Due to limitations of susceptibility testing and method updates, antibigrams are reflective of June – December 2024

1. [Central DuPage Hospital \(CDH\) Facility-Wide Antibigram](#)
2. [Central DuPage Hospital \(CDH\) Urinary Antibigram](#)
3. [Delnor Community Hospital \(DCH\) Facility-Wide Antibigram](#)
4. [Delnor Community Hospital \(DCH\) Urinary Antibigram](#)
5. [Kishwaukee/Valley West Hospitals \(KH/VW\) Facility-Wide Antibigram](#)
6. [Kishwaukee/Valley West Hospitals \(KH/VW\) Urinary Antibigram](#)

**CDH 2024**  
**June 1 - Dec 31**  
**Facility-Wide**  
**Antibiogram**



Isolates	Ampicillin <sup>a</sup>	Ampicillin/Sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftazidime	Ceftiozone	Ciprofloxacin	Clindamycin	Daptomycin	Levofloxacin	Linezolid	Meropenem	Oxacillin	Penicillin G	Piperacillin/Tazobactam	Sulfamethoxazole/Trimethoprim	Tetracycline	Tobramycin	Vancocin
<b>GRAM POSITIVES</b>																				
Enterococcus faecalis <sup>b</sup>	275	99																		98
Enterococcus faecium	51	35																		68
Staphylococcus aureus	379								68					68			94	84		100
Methicillin-resistant Staphylococcus aureus	121								53	100		100					85	68		100
Viridans streptococci	90														84					
<b>GRAM NEGATIVES</b>																				
Citrobacter freundii complex <sup>c</sup>	53		71		96	75	75	94			96		100			96	94			98
Citrobacter Koseri	43	100	95	97	100	100	100	100			100		100			100	97			100
Enterobacter cloacae complex <sup>c</sup>	114		74		93	76	71	92			97		100			100	86			95
Escherichia coli	1717	55	62	89	72 <sup>e</sup>	90	89	89	76		80		100			98	76			86
Klebsiella aerogenes <sup>c</sup>	58		86		93	80	77	98			98		100			87	100			100
Klebsiella oxytoca	95	65	85	22	89	87	84	87			93		98			88	84			91
Klebsiella pneumoniae	418	80	89	82 <sup>e</sup>	89	88	88	84			92		100			96	83			93
Proteus mirabilis	234	78	87	90	67 <sup>e</sup>	93	93	93	82		85		100			98	84			82
Pseudomonas aeruginosa	250		84		94	94		86					97			95				
Serratia	34		94		100	91	91	88			100		100			97	97			
<b>MULTI-DRUG RESISTANT GRAM NEGATIVES</b>																				
Extended-Spectrum $\beta$ -Lactamase Enterobacterales (ESBL-E) <sup>d</sup>	260							29			42		100				62			45


<sup>a</sup> Results of ampicillin susceptibility tests should be used to predict the activity of amoxicillin.

<sup>b</sup> Ampicillin may be used to predict susceptibility to amoxicillin-clavulanate, ampicillin-sulbactam, and piperacillin-tazobactam among non- $\beta$ -lactamase-producing enterococci in clinically stable/non-immunocompromised patients.

<sup>c</sup> High likelihood of ampC hyperproduction and eventual resistance to most beta-lactams; cefepime is empiric drug of choice for systemic infections

<sup>d</sup> Empiric treatment with a carbapenem is recommended for systemic infection (non-cystitis)

<sup>e</sup> Cefazolin systemic infection breakpoint, MIC  $\leq$  2 mcg/mL susceptible




Abbreviations: %S, percent susceptible; SDD, susceptible-dose-dependent; CLSI, Clinical and Laboratory Standards Institute

Less significant concerns for mortality within the next 24 to 48 hours (eg. uncomplicated UTIs or community-acquired infections), %S of 80-85% may be appropriate.

Antibiogram Guidance (CLSI M100-Ed33)

CDH 2024  
Jun 1 - Dec 31  
Urinary  
Antibiogram



Isolates	Ampicillin <sup>a</sup>	Ampicillin/Sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Levofloxacin	Meropenem	Nitrofurantoin	Oxacillin	Piperacillin/Tazobactam	Sulfamethoxazole/Trimethoprim	Tetracycline	Tobramycin	Vancomycin
<b>GRAM POSITIVES</b>																	
Enterococcus faecalis <sup>b</sup>	189	100						77			98						97
Enterococcus faecium	30	26						23			86						66
Staphylococcus aureus	39										92	61		87	82		100
<b>GRAM NEGATIVES</b>																	
Citrobacter freundii complex <sup>c</sup>	42		71		95	76	76	92	95	100	100		97	92		97	
Citrobacter koseri	32		93	96	100	100	100	100	100	100	87		100	100		100	
Enterobacter cloacae complex <sup>c</sup>	71		61		92	66	60	90	95	100	33		81	83		94	
Escherichia coli	1551	55	61	89	85	90	89	89	76	80	100	97	98	65		85	
Klebsiella aerogenes <sup>c</sup>	37			94		94	88	83	97	97	100	16		91	100		100
Klebsiella oxytoca	64			84	26	87	85	84	85	90	100	81		90	81		90
Klebsiella pneumoniae	345			87	86	88	87	87	82	91	100	45		96	81		92
Proteus spp.	191	76	85	87	85	92	92	91	82	85	100			98	85		81
Pseudomonas aeruginosa	114			84		95	96		84		98			97			
<b>MULTI-DRUG RESISTANT GRAM NEGATIVES</b>																	
Extended-Spectrum $\beta$ -Lactamase Enterobacterales (ESBL-E) <sup>d</sup>	234								28	41	100	71			43		62

<sup>a</sup> Results of ampicillin susceptibility tests should be used to predict the activity of amoxicillin.

<sup>b</sup> Ampicillin may be used to predict susceptibility to amoxicillin-clavulanate, ampicillin-sulbactam, and piperacillin-tazobactam among non- $\beta$ -lactamase-producing enterococci in clinically stable/non-immunocompromised patients.


<sup>c</sup> High likelihood of ampC hyperproduction and eventual resistance to most beta-lactams; cefepime is empiric drug of choice for systemic infections

<sup>d</sup> Empiric treatment with a carbapenem is recommended for systemic infection (non-cystitis)


Abbreviations: %S, percent susceptible; SDD, susceptible-dose-dependent; CLSI, Clinical and Laboratory Standards Institute

Less significant concerns for mortality within the next 24 to 48 hours (eg. uncomplicated UTIs or community-acquired infections), %S of 80-85% may be appropriate.

Antibiogram Guidance (CLSI M100-Ed33)



DCH 2024  
June 1 - Dec 31  
Facility-Wide  
Antibiogram



Isolates	Ampicillin <sup>a</sup>	Ampicillin/Sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin	Levofloxacin	Linezolid	Meropenem	Oxacillin	Penicillin G	Piperacillin/Tazobactam	Sulfamethoxazole/Trimethoprim	Tetracycline	Tobramycin	Vancomycin
<b>GRAM POSITIVES</b>																				
Enterococcus species <sup>b</sup>	151	96																		99
Enterococcus faecalis <sup>b</sup>	137	98																		97
Staphylococcus aureus	190								65					66			94	78		100
Methicillin-resistant Staphylococcus aureus	66								44	95		100					84	57		100
Viridans streptococci	33														100					
<b>GRAM NEGATIVES</b>																				
Citrobacter freundii complex <sup>c</sup>	30			70		90	66	66	93			96	100				93	96		100
Enterobacter cloacae complex <sup>c</sup>	52			76		90	75	67	94			98	100				80	94		96
Escherichia coli	748	58	63	90	74 <sup>e</sup>	91	89	89	76			80	100				98	79		86
Klebsiella oxytoca	56		75	91	33	98	98	92	98			98	100				94	91		96
Klebsiella pneumoniae	194		84	95	84 <sup>e</sup>	95	95	95	89			95	100				95	89		95
Proteus mirabilis	100	69	76	88	63 <sup>e</sup>	89	89	88	78			80	100				100	86		81
Pseudomonas aeruginosa	136			86		92	92		84				99				91			
<b>MULTI-DRUG RESISTANT GRAM NEGATIVES</b>																				
Extended-Spectrum $\beta$ -Lactamase Enterobacterales (ESBL-E) <sup>d</sup>	100								29				42		100			44		58


<sup>a</sup> Results of ampicillin susceptibility tests should be used to predict the activity of amoxicillin.

<sup>b</sup> Ampicillin may be used to predict susceptibility to amoxicillin-clavulanate, ampicillin-sulbactam, and piperacillin-tazobactam among non- $\beta$ -lactamase-producing enterococci in clinically stable/non-immunocompromised patients.

<sup>c</sup> High likelihood of ampC hyperproduction and eventual resistance to most beta-lactams; cefepime is empiric drug of choice for systemic infections

<sup>d</sup> Empiric treatment with a carbapenem is recommended for systemic infection (non-cystitis)

<sup>e</sup> Cefazolin systemic infection breakpoint, MIC  $\leq$ 2 mcg/mL susceptible




Abbreviations: %S, percent susceptible; SDD, susceptible-dose-dependent; CLSI, Clinical and Laboratory Standards Institute

Less significant concerns for mortality within the next 24 to 48 hours (eg. uncomplicated UTIs or community-acquired infections), %S of 80-85% may be appropriate.

Antibiogram Guidance (CLSI M100-Ed33)

**DCH 2024**  
**Jun 1 - Dec 31**  
**Urinary**  
**Antibiogram**



Isolates	Ampicillin <sup>a</sup>	Ampicillin/Sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Levofloxacin	Meropenem	Nitrofurantoin	Oxacillin	Piperacillin/Tazobactam	Sulfamethoxazole/Trimethoprim	Tetracycline	Tobramycin	Vancomycin
<b>GRAM POSITIVES</b>																	
Enterococcus faecalis <sup>b</sup>	81	97						55			98						95
<b>GRAM NEGATIVES</b>																	
Citrobacter freundii complex <sup>c,e</sup>	22		72		90	68	68	90	95	100	90		95	95		100	
Citrobacter koseri <sup>c,e</sup>	16		87	100	87	100	100	93	93	100	81		100	93		100	
Enterobacter cloacae complex <sup>c,e</sup>	24		62		83	58	50	95	95	100	41		66	91		95	
Escherichia coli	678	58	62	89	85	90	89	89	76	80	100	97		98	79		85
Klebsiella aerogenes <sup>c,e</sup>	13			84		100	84	76	100	100	100	30		84	100		100
Klebsiella oxytoca	41		78	90	36	97	97	90	97	97	100	85		92	90		95
Klebsiella pneumoniae	169		85	95	94	95	95	95	89	94	100	46		95	89		95
Proteus spp.	80	68	75	86	70	89	89	87	77	80	100			100	87		81
Pseudomonas aeruginosa	56			85		94	94		92		100			91			
<b>MULTI-DRUG RESISTANT GRAM NEGATIVES</b>																	
Extended-Spectrum $\beta$ -Lactamase Enterobacterales (ESBL-E) <sup>d</sup>	87								26	39	100	74			44		58


<sup>a</sup> Results of ampicillin susceptibility tests should be used to predict the activity of amoxicillin.

<sup>b</sup> Ampicillin may be used to predict susceptibility to amoxicillin-clavulanate, ampicillin-sulbactam, and piperacillin-tazobactam among non- $\beta$ -lactamase-producing enterococci in clinically stable/non-immunocompromised patients.

<sup>c</sup> High likelihood of ampC hyperproduction and eventual resistance to most beta-lactams; cefepime is empiric drug of choice for systemic infections

<sup>d</sup> Empiric treatment with a carbapenem is recommended for systemic infection (non-cystitis)

<sup>e</sup> Less than 30 isolates, interpret with caution




Abbreviations: %S, percent susceptible; SDD, susceptible-dose-dependent; CLSI, Clinical and Laboratory Standards Institute

Less significant concerns for mortality within the next 24 to 48 hours (eg. uncomplicated UTIs or community-acquired infections), %S of 80-85% may be appropriate.

Antibiogram Guidance (CLSI M100-Ed33)

**KH/VW 2024**  
**June 1 - Dec 31**  
**Facility-Wide**  
**Antibiogram**



Isolates	Ampicillin <sup>a</sup>	Ampicillin/Sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin	Levofloxacin	Linezolid	Meropenem	Oxacillin	Penicillin G	Piperacillin/Tazobactam	Sulfamethoxazole/Trimethoprim	Tetracycline	Tobramycin	Vancomycin
<b>GRAM POSITIVES</b>																				
Enterococcus species <sup>b</sup>	133	96																		99
Enterococcus faecalis <sup>b</sup>	124	97																		97
Staphylococcus aureus	184								63					63			95	86		100
Methicillin-resistant Staphylococcus aureus	71								43	100		100					88	76		100
<b>GRAM NEGATIVES</b>																				
Enterobacter cloacae complex <sup>c</sup>	45			77		93	84	77	95			97		100			84	86		97
Escherichia coli	839	59	66	92	74 <sup>e</sup>	92	92	91	78			82		100			98	81		88
Klebsiella oxytoca	36		75	94	41	97	97	97	91			94		100			100	86		94
Klebsiella pneumoniae	189		84	95	85 <sup>e</sup>	95	94	94	88			92		100			98	88		94
Proteus mirabilis	87	80	86	94	62 <sup>e</sup>	94	94	94	66			67		100			100	75		74
Pseudomonas aeruginosa	85			84		90	92		77					98			92			
<b>MULTI-DRUG RESISTANT GRAM NEGATIVES</b>																				
Extended-Spectrum $\beta$ -Lactamase Enterobacterales (ESBL-E) <sup>d</sup>	102								20			32		100				48		54


<sup>a</sup> Results of ampicillin susceptibility tests should be used to predict the activity of amoxicillin.

<sup>b</sup> Ampicillin may be used to predict susceptibility to amoxicillin-clavulanate, ampicillin-sulbactam, and piperacillin-tazobactam among non- $\beta$ -lactamase-producing enterococci in clinically stable/non-immunocompromised patients.

<sup>c</sup> High likelihood of ampC hyperproduction and eventual resistance to most beta-lactams; cefepime is empiric drug of choice for systemic infections

<sup>d</sup> Empiric treatment with a carbapenem is recommended for systemic infection (non-cystitis)

<sup>e</sup> Cefazolin systemic infection breakpoint, MIC  $\leq$  2 mcg/mL susceptible




Abbreviations: %S, percent susceptible; SDD, susceptible-dose-dependent; CLSI, Clinical and Laboratory Standards Institute

Less significant concerns for mortality within the next 24 to 48 hours (eg. uncomplicated UTIs or community-acquired infections), %S of 80-85% may be appropriate.

Antibiogram Guidance (CLSI M100-Ed33)

**KH/VW 2024**  
**Jun 1 - Dec 31**  
**Urinary**  
**Antibiogram**



Isolates	Ampicillin <sup>a</sup>	Ampicillin/Sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Levofloxacin	Meropenem	Nitrofurantoin	Oxacillin	Piperacillin/Tazobactam	Sulfamethoxazole/Trimethoprim	Tetracycline	Tobramycin	Vancomycin
<b>GRAM POSITIVES</b>																	
Enterococcus faecalis <sup>b</sup>	100	97						81			98						98
Staphylococcus aureus	31										96	45		93	80		100
<b>GRAM NEGATIVES</b>																	
Citrobacter freundii complex <sup>c,e</sup>	24			79		100	79	75	87	100	100	87		95	87		100
Enterobacter cloacae complex <sup>c</sup>	31			74		96	80	74	100	100	100	25		77	83		100
Escherichia coli	800	59	66	51	88	92	92	91	78	82	100	96		98	81		87
Klebsiella aerogenes <sup>c,e</sup>	22			86		90	81	81	100	100	100	36		86	95		100
Klebsiella oxytoca <sup>c,e</sup>	29			96	44	96	96	96	89	93	100	93		100	82		93
Klebsiella pneumoniae	174		84	95	93	95	94	94	89	93	100	40		98	88		95
Proteus spp.	70	83	88	90	88	92	92	88	64	65	100			100	77		74
Pseudomonas aeruginosa	52			82		94	98		76		100			96			
<b>MULTI-DRUG RESISTANT GRAM NEGATIVES</b>																	
Extended-Spectrum $\beta$ -Lactamase Enterobacterales (ESBL-E) <sup>d</sup>	94								20	30	100	65			50		52


<sup>a</sup> Results of ampicillin susceptibility tests should be used to predict the activity of amoxicillin.

<sup>b</sup> Ampicillin may be used to predict susceptibility to amoxicillin-clavulanate, ampicillin-sulbactam, and piperacillin-tazobactam among non- $\beta$ -lactamase-producing enterococci in clinically stable/non-immunocompromised patients.

<sup>c</sup> High likelihood of ampC hyperproduction and eventual resistance to most beta-lactams; cefepime is empiric drug of choice for systemic infections

<sup>d</sup> Empiric treatment with a carbapenem is recommended for systemic infection (non-cystitis)

<sup>e</sup> Less than 30 isolates, interpret with caution



Abbreviations: %S, percent susceptible; SDD, susceptible-dose-dependent; CLSI, Clinical and Laboratory Standards Institute

Less significant concerns for mortality within the next 24 to 48 hours (eg. uncomplicated UTIs or community-acquired infections), %S of 80-85% may be appropriate.

Antibiogram Guidance (CLSI M100-Ed33)